Pages Menu
TwitterRssFacebook
Categories Menu

Posted by on Jun 14, 2013 in Medical Journals |

Interferon-α treatment in systemic mastocytosis.

Head for The Masto Townhall forum to debate this paper.
This article may be copyrighted. Notice to copyright holders.
You can view the full article at the publisher here
There is a fee associated with downloading this article.
Curr Drug Targets. 2011 Mar 1;12(3):433-6.

Interferon-α treatment in systemic mastocytosis.

Bjerrum OW.

Abstract

Patients with systemic mastocytosis are rare, constitute a heterogeneous clinical entity and some may not require treatment until long after diagnosis. However, most patients who present with disabling symptoms, organ involvement and fulfill B or C findings as outlined in the 2008 WHO classification need treatment. This review on interferon treatment in systemic mastocytosis documents an effect of this biological agent in some patients with mastocytosis. However, the place of interferon-α, as mono- or combination therapy, in the treatment algorithm may only be definitely established in multicenter studies, which are based on the principles of controlled clinical trials.

PMID: 21143153 [PubMed – indexed for MEDLINE]